Heart failure & cardiomyopathies
Comparison of Cardiovascular Outcomes of New Antihyperglycemic Agents in Type 2 Diabetes Mellitus: A Meta-Analysis
Authors' conclusion
SGLT2i is associated with a lower risk of cardiovascular death, HHF, death from any cause, and MI in patients with T2DM compared with GLP1-RA. In addition, SGLT2i brought more benefits with respect to the effects of cardiovascular death, HHF, and death from any cause in patients with HF, regardless of diabetes status.
Study context
- Population
- T2DM patients with CV risk; patients with heart failure (HF) regardless of diabetes status38 studies
- Comparison
- SGLT2i vs GLP1-RA in T2DM; SGLT2i vs control in HF
- Outcome
- CV outcomes, SGLT2i vs GLP1-RA (T2DM)
Pooled result
As reported in the abstract
SGLT2i vs GLP1-RARelative risk (95% CI)
HHF
0.77(0.74–0.80)
Death from any cause
0.64(0.60–0.68)
MI
0.81(0.76–0.87)
- CV death; CI as printed (does not contain estimate)
- RR 0.59 (95% CI 0.44–0.58)
Further pooled results
| Outcome | RR (95% CI) | |
|---|---|---|
| CV death, HHF, death from any cause in HF, SGLT2i vs controlCV death (reduced by 14%) · regardless of diabetes status | 0.86 (0.79–0.94) | |
| 0.512Relative risk (log scale) |
- CV death, hospitalization of heart failure (HHF), death from any cause in HF, SGLT2i vs control — HHF risk reduced
- 25%
- CV death, HHF, death from any cause in HF, SGLT2i vs control — Death from any cause risk reduced
- 9%
Safety
| Outcome | RR (95% CI) | |
|---|---|---|
| Stroke, SGLT2i vs GLP1-RAIncreased risk | 1.10 (1.04–1.17) | |
| 0.512Relative risk (log scale) |
Original publication
Comparison of Cardiovascular Outcomes of New Antihyperglycemic Agents in Type 2 Diabetes Mellitus: A Meta-Analysis. ESC Heart Fail. Published 28 February 2024. doi:10.
Summarised from the published abstract; every number is checked against it